Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fuji
Medtronic
Cerilliant
Mallinckrodt
Chinese Patent Office
Johnson and Johnson
AstraZeneca
UBS
Citi

Generated: October 20, 2017

DrugPatentWatch Database Preview

VFEND Drug Profile

« Back to Dashboard

Which patents cover Vfend, and when can generic versions of Vfend launch?

Vfend is a drug marketed by Pf Prism Cv and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has sixty patent family members in forty-six countries and three supplementary protection certificates in three countries.

The generic ingredient in VFEND is voriconazole. There are thirteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the voriconazole profile page.

Summary for Tradename: VFEND

US Patents:1
Applicants:1
NDAs:3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list62
Clinical Trials: see list15
Patent Applications: see list3,144
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VFEND at DailyMed

Pharmacology for Tradename: VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
VFEND
voriconazole
FOR SUSPENSION;ORAL021630-001Dec 19, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002APRXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
FOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
FOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VFEND

Drugname Dosage Strength RLD Submissiondate
voriconazoleOral Suspension40 mg/mLVfend10/8/2010
voriconazoleFor Injection200 mg/vialVfend9/12/2008
voriconazoleTablets50 mg and 200 mgVfend4/14/2008

International Patent Family for Tradename: VFEND

Country Document Number Estimated Expiration
China1261287► Subscribe
Eurasian Patent Organization001924► Subscribe
Bulgaria64584► Subscribe
New Zealand501066► Subscribe
Poland191295► Subscribe
Panama8453201► Subscribe
Australia724799► Subscribe
Canada2295035► Subscribe
Slovakia159399► Subscribe
Serbia49633► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VFEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/031United Kingdom► SubscribePRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
2003005Lithuania► SubscribePRODUCT NAME: VORICONAZOLIS; REGISTRATION NO/DATE: 02/7890/8 20021002
C0030France► SubscribePRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Queensland Health
Argus Health
Dow
Mallinckrodt
Chinese Patent Office
McKesson
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot